Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This pilot and feasibility study studies how well nivolumab and combination chemotherapy work
before surgery in treating patients with pancreatic cancer that could possibly be removed by
surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride,
leucovorin calcium and oxaliplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving nivolumab in combination with chemotherapy before surgery may work better
in treating patients with pancreatic cancer compared to chemotherapy alone.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI) NovoCure Ltd.